Back to results
US 2022/0016210 A1Published application
Aflibercept formulations and uses thereof
AssigneeJust-Evotec Biologics, Inc.
InventorsBruce A. Kerwin, Julee A. Floyd, Alison J. Gillespie, Christine C. Siska
Life of this patent
Estimating the term…
Abstract
Ophthalmic formulations comprising aflibercept are disclosed that are suitable for a method of treatment of an eye disorder or disease by intravitreal or topical administration.
Claims19
1-27. (canceled)
An ophthalmic formulation, comprising:
- (a) aflibercept;
- (b) a histidine buffer;
- (c) a non-ionic surfactant;
- (d) a tonicifying agent comprising a polyol or an amino acid, wherein the formulation has a final osmolality of about 300 mOsm/kg;
- (e) an additional amino acid stabilizing agent selected from the group consisting of proline, arginine, methionine, lysine and mixtures thereof;
- and
- wherein the pH of the formulation is about pH 5.0 to about pH 6.5.
4 more elements
Dependencies are inferred from the claim text.